Brief: Arca Biopharma Announces Rnapc2 Covid-19 Patent Assignment Agreement

Oruka Therapeutics

07/07/2021 13:10

July 7 (Reuters) - ARCA Biopharma Inc  ABIO.O :
    * ARCA BIOPHARMA ANNOUNCES RNAPC2 COVID-19 PATENT ASSIGNMENT
AGREEMENT
    * ARCA BIOPHARMA INC - ENTERED INTO A PATENT ASSIGNMENT
AGREEMENT
WITH UNIVERSITY MEDICAL CENTER OF JOHANNES GUTENBERG UNIVERSITY
MAINZ, GERMANY
    * ARCA BIOPHARMA - UNDER AGREEMENT, CO RECEIVES EXCLUSIVE
WORLD-WIDE PATENT RIGHTS TO USE RNAPC2 AS POTENTIAL TREATMENT
FOR COVID-19, & OTHER INDICATIONS
    * ARCA BIOPHARMA - CO HAS POTENTIAL UPFRONT & MILESTONE
OBLIGATIONS THAT COULD TOTAL ABOUT EUR 1.6 MILLION & ROYALTY
OBLIGATIONS IN LOW SINGLE DIGIT RANGE
    * ARCA BIOPHARMA - CO OBTAINS OPTION TO ACQUIRE WORLD-WIDE
PATENT
RIGHTS TO DISCOVERIES TO USE RNAPC2 AS POTENTIAL THERAPEUTIC FOR
AUTO-IMMUNE DISORDERS

Source text for Eikon:  ID:nGNX99LywT 
Further company coverage:  ABIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))